Hansa Biopharma Completes Enrollment in Anti-GBM

The completion of enrollment in the anti-GBM study marks an important milestone for the Company's expansion outside transplantation. Anti-GBM is a rare immunological disease with a significant unmet medical need

LUND, Sweden, Jan. 27, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the patient enrollment in an investigator-initiated phase 2 study to evaluate safety, tolerability and efficacy of imlifidase in 15 patients with severe Anti-GBM antibody disease has now been completed. A first data read out is expected in the third quarter of 2020.

"I am very pleased that we have now completed the enrollment of patients in the Anti-GBM antibody disease study. This marks an important milestone in Hansa Biopharma's efforts to develop potentially lifesaving and lifealtering therapies for patients with rare immunological diseases within a range of therapeutic areas, where there is a significant unmet medical need," says Søren Tulstrup, President and CEO, Hansa Biopharma. "Anti-GBM is the first IgG-mediated disease outside transplantation, where imlifidase is being investigated to potentially stop an immunologic attack."

Anti-GBM antibody disease, also known as Goodpasture's disease, is a severe kidney disease where the immune system mistakenly develops IgG-antibodies, resulting in an acute immune attack on the kidneys and in some patients also on the lungs. Severe Anti-GBM antibody disease may progress to renal failure or death. Most of the patients are experiencing significant loss of kidney function requiring chronic dialysis and kidney transplantation. Anti-GBM antibody disease affects roughly one in a million annually.

Hansa Biopharma was granted orphan drug designation for imlifidase for Anti-GBM antibody disease in both the EU and the US in 2018. 

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46-(0)-709-298 269
E-mail: klaus.sindahl@hansabiopharma.com

Rolf Gulliksen, Head of Corporate Communications
Hansa Biopharma
Mobile: +46-(0)-733-328 634
E-mail: rolf.gulliksen@hansabiopharma.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-completes-enrollment-in-anti-gbm,c3017355

The following files are available for download:

https://mb.cision.com/Main/1219/3017355/1179919.pdf

Hansa Biopharma completes enrollment in anti-GBM

 

 

Cision

View original content:http://www.prnewswire.com/news-releases/hansa-biopharma-completes-enrollment-in-anti-gbm-300993337.html

SOURCE Hansa Biopharma AB